Outcome in Patients Treated with Intraarterial Thrombectomy - OptiMAL Blood Pressure Control (OPTIMAL-BP)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

306 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-18

Study Completion Date

2023-07-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent endovascular thrombectomy (EVT) trial have proven the effectiveness of intraarterial revascularization in patients with larger cerebral artery occlusion. The success rate of EVT is close to 80%, but only 50% of patients improve to independent functional outcome. Therefore, new treatment strategies are needed to reduce the futile revascularization. However, updated guidelines recommend the indications for EVT based on the results of randomized clinical trials (RCT), management of post-revascularization is largely unknown.

Current guidelines suggest that systolic blood pressure should be adjusted below 180 mmHg and diastolic blood pressure below 105 mmHg in patients undergoing intraarterial reopening. However, in the case of successful recanalization by EVT, same guideline is adopted even though the possibility of intracerebral hemorrhage or reperfusion injury by high blood pressure. On the other hand, too low blood pressure can worsen cerebral ischemia.

Therefore, this study will compare the effectiveness of active blood pressure control group (with less than 140 mmHg systolic blood pressure) versus standard blood pressure control group (with less than 180 mmHg systolic blood pressure) during the first 24 hours in patients who underwent EVT and achieved successful recanalization (TICI 2b-3). The goal is to reach the target blood pressure within 60 minutes of randomization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intensive Blood Pressure Control in Ischaemic Stroke Patients With Severe Cerebral Small Vessel Disease

NCT05690997

Small Vessel Cerebrovascular Disease Stroke

UNKNOWN NA

Blood Pressure Control in Acute Ischemic Stroke

NCT03443596

Blood Pressure Acute Stroke

COMPLETED PHASE2/PHASE3

The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease

NCT01321749

Cerebrovascular Disease

COMPLETED PHASE1/PHASE2

Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients

NCT04036409

Ischemic Stroke Blood Pressure Cognitive Impairment +1 more

ACTIVE_NOT_RECRUITING NA

IDEAL Blood Pressure Management During Endovascular Therapy for Acute Ischemic Stroke

NCT04749251

Acute Ischemic Stroke

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. The study is a multicenter, prospective, randomized, open-label trial with blinded end-point assessment (PROBE) design study.
2. After successful revascularization, the active blood pressure control group and the standard blood pressure control group will be randomized by 1: 1.
3. Patients who is admitted to the Department of Neurology at the participating hospital with acute cerebral infarction will will be included for 5 years from December 2019 to December 2023 (based on the date of stroke). Patients who have undergone intraarterial thrombectomy and have successfully reopened arteries should be enrolled.
4. Collect medical history, laboratory findings and blood pressure parameters (systolic blood pressure, diastolic blood pressure, blood pressure variability, etc.), neurological scores, functional recovery, and quality of life indicators.
5. Neurological scores, functional recovery scores, and quality of life indicators are performed by independent researchers in the blind state.
6. All data is collected using e-CRF, and the image study will be anonymized and sent to the central adjudication.
7. Central adjudication will review the image study.
8. One intermediate analysis will be conducted at the end of first period or when a half of study patients were enrolled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1. The study is a multicenter, prospective, randomized, open-label trial with blinded end-point assessment (PROBE) design study.
2. After successful revascularization, the active blood pressure control group and the standard blood pressure control group will be randomized by 1: 1.
3. Patients who have undergone intraarterial thrombectomy due to acute cerebral infarction and have successfully reopened arteries will be enrolled.
4. Medical history, laboratory findings and blood pressure parameters (systolic blood pressure, diastolic blood pressure, blood pressure variability, etc.), neurological scores, functional recovery, and quality of life indicators will be collected.
5. Neurological scores, functional recovery scores, and quality of life indicators are performed by independent researchers in the blind state.
6. All data is collected using e-CRF, and the image study will be anonymized and sent to the central adjudication.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Three months after discharge, the independence assessment will be performed by the researcher who don't know the patients group.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional blood pressure control group

systolic blood pressure \<180 mmHg

Group Type ACTIVE_COMPARATOR

conventional blood pressure control (labetalol, nicardipine)

Intervention Type DRUG

After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.

Intensive blood pressure control group

systolic blood pressure \<140 mmHg

Group Type EXPERIMENTAL

intensive blood pressure control (labetalol, nicardipine)

Intervention Type DRUG

After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<140 mmHg.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

conventional blood pressure control (labetalol, nicardipine)

After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.

Intervention Type DRUG

intensive blood pressure control (labetalol, nicardipine)

After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<140 mmHg.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥20 years
2. Acute ischemic stroke patients who underwent intraarterial treatment for large vessel occlusion. (ICA, MCA M1 or M2, ACA A1, PCA P1)
3. Patients with successful recanalization after intraarterial thrombectomy (TICI 2b or TICI 3) 4. Patients with elevated BP (systolic BP ≥140 mmHg) on at least two measurements with a two-minute interval within 2 hours of successful recanalization.

Exclusion Criteria

1. Age \<20
2. Patients with contraindication for use antihypertensive medication after intraarterial thrombectomy.
3. Patients with blood pressure \<140 mmHg after successful recanalization.
4. Patients with symptomatic intracranial hemorrhage after successful recanalization
5. Patients with pre-morbid neurological dysfunction (modified Rankin Scale, mRS \>2)
6. Patients with severe medical and surgical diseases.
7. Patients who are considered having a difficulty to enrollment.
8. No informed consents from patients.
9. Patients who participated in a study that did not allow duplicate participation

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No